All Brands Owned by Pfizer

Pfizer's single-pill combination of amlodipine besylate (Norvasc) and atorvastatin calcium (Lipitor), FDA approved January 30, 2004, as the first dual-therapy product combining a calcium channel blocker and a statin in one tablet for patients requiring treatment for both hypertension and dyslipidemia, with generic amlodipine/atorvastatin now widely available.

Prescription anti-inflammatory medication for treating arthritis pain and inflammation, manufactured and marketed by Pfizer.

Pfizer's prescription smoking cessation medication (varenicline), FDA approved May 11, 2006, that works as a partial agonist at alpha4beta2 nicotinic acetylcholine receptors, subject to a black box warning for neuropsychiatric effects and a full recall in September 2021 due to nitrosamine impurities, with generic varenicline now widely available.

Prescription antifungal medication for treating fungal infections including candidiasis and cryptococcal meningitis, manufactured and marketed by Pfizer.

Generic prescription folinic acid (5-formyltetrahydrofolate) used for methotrexate rescue in high-dose methotrexate chemotherapy, as a biochemical modulator of fluorouracil (5-FU) in colorectal cancer regimens including FOLFOX and FOLFIRI, and for treatment of megaloblastic anemia; originally developed by Lederle Laboratories in the 1940s and now manufactured by multiple pharmaceutical companies including Pfizer/Hospira, Teva, and Fresenius Kabi.

Pfizer's brand name for atorvastatin, the world's best-selling prescription drug from 1996 to 2012, generating over $125 billion in cumulative sales as a cholesterol-lowering statin medication.

Pfizer's brand name for pregabalin, a neuropathic pain and fibromyalgia treatment approved by the FDA in 2004, now owned by Viatris following the 2020 Upjohn spinoff and Mylan merger.

Prescription calcium channel blocker medication for treating high blood pressure and angina, manufactured and marketed by Pfizer.

Merck's 23-valent pneumococcal polysaccharide vaccine (PPSV23), FDA approved in 1983 as an expansion of Merck's 14-valent formulation licensed in 1977, providing T-cell independent immune protection against 23 pneumococcal serotypes in adults aged 50 and older and high-risk individuals, now used alongside conjugate vaccines per updated CDC recommendations.

Pfizer's pneumococcal conjugate vaccine franchise, originally developed by Wyeth as Prevnar (PCV7, FDA approved February 17, 2000), succeeded by Prevnar 13 (PCV13, FDA approved February 24, 2010) and Prevnar 20 (PCV20, FDA approved June 8, 2021), one of the world's best-selling vaccines with peak annual revenues exceeding $6 billion.

Pfizer's brand name for sildenafil, the first oral erectile dysfunction treatment approved by the FDA in 1998, now owned by Viatris following the 2020 Upjohn spinoff and Mylan merger.

Pfizer's oral JAK inhibitor (tofacitinib), FDA approved November 6, 2012, as the first JAK inhibitor approved in the United States, indicated for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, juvenile idiopathic arthritis, and ankylosing spondylitis, subject to a strengthened black box warning in September 2021 following the ORAL Surveillance trial showing increased risks of serious cardiovascular events, cancer, blood clots, and death compared to TNF inhibitors.

Pfizer's macrolide antibiotic (azithromycin), originally discovered by Pliva in 1980 and licensed to Pfizer, FDA approved in June 1991, widely known as the Z-Pack for its 5-day oral course, with generic azithromycin available since 2005 following patent expiration and a 2013 FDA safety warning regarding QT prolongation risk.